Roche said phase III data supports benefit/risk profile of Hemlibra
ZURICH, July 19 (Reuters) - Analysis of data from a phase IIIb clinical study further supports the benefit/risk profile of Hemlibra in patients with haemophilia A, with no new safety signals identified, Swiss drugmaker Roche Holding ROG.S said on Monday.
Hemlibra also continued to demonstrate effective bleed control, with nearly 83% of participants achieving zero treated bleeds, Roche said.
(Reporting by Michael Shield, editing by Silke Koltrowitz)
((firstname.lastname@example.org; +41 41 528 3638;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.